# Vortosiran in Atrial Fibrillation

Study · id `cardio:ct-nct07870889` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07870889](<https://clinicaltrials.gov/study/NCT07870889>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07870889

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07870889. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2028-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07870889, source copy `cardio:ctgov-nct07870889-2026-10-13`, retrieved 2026-10-26)
- Planned start: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT07870889, source copy `cardio:ctgov-nct07870889-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2028-07-31 (anticipated) (ClinicalTrials.gov record NCT07870889, source copy `cardio:ctgov-nct07870889-2026-10-13`, retrieved 2026-10-26)
- Completion: 2028-08-31 (anticipated) (ClinicalTrials.gov record NCT07870889, source copy `cardio:ctgov-nct07870889-2026-10-13`, retrieved 2026-10-26)
- Countries: Denmark; Norway; Poland; Sweden (ClinicalTrials.gov record NCT07870889, source copy `cardio:ctgov-nct07870889-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07870889-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vortosiran in Atrial Fibrillation
- Condition: Non-valvular Atrial Fibrillation (AF)
- Intervention (Drug): Vortosiran
- Intervention (Drug): Vortosiran
- Intervention (Drug): Apixaban
- Lead sponsor: Ribocure Pharmaceuticals AB
- Lead sponsor class: INDUSTRY
- Collaborator: Link Medical Research AB
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Ribocure Pharmaceuticals AB (`cardio:org-ribocure-pharmaceuticals-ab`)

## Provenance

Content hash: 87f79ede2a2b715ecd5050dee6fa4bf0f7d7bb2db77755b76e072d21b853cad2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
